Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Carboplatin in pediatrics].

F Doz1

  • 1Institut Curie, département d'oncologie pédiatrique, Paris. Francois.Doz@Curie.net

Bulletin Du Cancer
|November 18, 2000
PubMed
Summary
This summary is machine-generated.

Carboplatin is frequently used for pediatric solid tumors due to fewer side effects than cisplatin. Dosing formulas and long-term monitoring are crucial for effective and safe carboplatin treatment in children.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retinoblastoma: From genes to patient care.

European journal of medical genetics·2022
Same author

Imaging Features with Histopathologic Correlation of CNS High-Grade Neuroepithelial Tumors with a <i>BCOR</i> Internal Tandem Duplication.

AJNR. American journal of neuroradiology·2021
Same author

Focal Areas of High Signal Intensity in Children with Neurofibromatosis Type 1: Expected Evolution on MRI.

AJNR. American journal of neuroradiology·2020
Same author

Indications and results of diagnostic biopsy in pediatric renal tumors: A retrospective analysis of 317 patients with critical review of SIOP guidelines.

Pediatric blood & cancer·2019
Same author

Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures.

Scientific reports·2017
Same author

[Retinoblastoma update].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2015
Same journal

[Update: Evolution in the management of metastatic urothelial carcinomas].

Bulletin du cancer·2026
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
See all related articles

Area of Science:

  • Pediatric Oncology
  • Pharmacology
  • Clinical Therapeutics

Context:

  • Carboplatin is increasingly utilized for pediatric solid tumors, offering a favorable risk profile compared to cisplatin, particularly regarding renal and otologic toxicity.
  • While its efficacy is established in combination regimens, monotherapy studies in children are limited.
  • High-dose carboplatin with stem cell rescue is a key application, though limited by hematologic toxicity.

Purpose:

  • To review the current use, dosing strategies, and long-term implications of carboplatin in pediatric oncology.
  • To highlight the advantages of carboplatin over cisplatin in pediatric cancer treatment.
  • To emphasize the importance of individualized dosing and follow-up for carboplatin therapy.

Summary:

  • Carboplatin is a preferred platinum agent in pediatric solid tumors due to reduced toxicity.

Related Experiment Videos

  • Specialized pediatric dosing formulas targeting area under the curve (AUC) enable personalized therapy.
  • High-dose carboplatin necessitates careful management due to hematologic toxicity and requires hematopoietic stem cell support.

    • Impact:

    • Carboplatin offers a safer alternative for treating childhood cancers.
    • Individualized dosing improves therapeutic outcomes and minimizes adverse effects.
    • Mandatory long-term follow-up is essential to monitor for potential mutagenic and hypofecundity risks.